As such, the CPXV infection model of hemorrhagic smallpox provides an opportunity to evaluate the effectiveness of immunomodulators targeting CCL2 and other pro-inflammatory mediators during progression of viral-induced hemorrhagic diseases. This evidence concerns the gene CCL2 and smallpox.